SHC vs. PGNY, RDNT, AGL, QGEN, DVA, AMED, IDYA, BHVN, TXG, and IRTC
Should you be buying Sotera Health stock or one of its competitors? The main competitors of Sotera Health include Progyny (PGNY), RadNet (RDNT), agilon health (AGL), Qiagen (QGEN), DaVita (DVA), Amedisys (AMED), IDEAYA Biosciences (IDYA), Biohaven (BHVN), 10x Genomics (TXG), and iRhythm Technologies (IRTC). These companies are all part of the "medical" sector.
Sotera Health (NASDAQ:SHC) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability.
Sotera Health currently has a consensus target price of $17.70, indicating a potential upside of 56.78%. Progyny has a consensus target price of $43.11, indicating a potential upside of 53.47%. Given Sotera Health's higher probable upside, equities research analysts plainly believe Sotera Health is more favorable than Progyny.
In the previous week, Progyny had 27 more articles in the media than Sotera Health. MarketBeat recorded 27 mentions for Progyny and 0 mentions for Sotera Health. Progyny's average media sentiment score of 0.13 beat Sotera Health's score of 0.00 indicating that Progyny is being referred to more favorably in the news media.
Progyny has higher revenue and earnings than Sotera Health. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
Progyny has a net margin of 5.53% compared to Sotera Health's net margin of 5.09%. Sotera Health's return on equity of 48.47% beat Progyny's return on equity.
Sotera Health has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.
Progyny received 42 more outperform votes than Sotera Health when rated by MarketBeat users. Likewise, 75.00% of users gave Progyny an outperform vote while only 56.96% of users gave Sotera Health an outperform vote.
91.0% of Sotera Health shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 55.1% of Sotera Health shares are owned by company insiders. Comparatively, 12.3% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Progyny beats Sotera Health on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sotera Health Competitors List
Related Companies and Tools
